RE:Interesting conversation My wife is being treated at Princess Margaret Hospital for Ovarian Cancer. Princess Margaret is part of the University Health Network and considered one of the top 5 research hospitals in the world. I asked my wife's oncologist about the PDC and I asked several of the fellows. None even knew what Sortilin was. They knew that a PDC was kind of like an ADC.
Bucknelly21 wrote: So unlike some here I am not scientifically inclined, however I do understand what we have and how it works. Last night I was at a charity event for an athlete in Seattle. His charity is big into cancer research at Seattle children's hospital. They had two of the main doctors here. They have been treating children with T cell therapy and having some success. I felt like it was a good opportunity to ask about their thoughts on pdc treatment ect. Needles to say they were convinced that targeted therapy was the future of oncology. They both didn't know much about pdc so I began to explain the platform to them and how it worked ect. They both thought it was extremely impressive to get fast track pre clinical. They were both adamant that at the point we are even if no data is reported on efficacy that have super low toxicity outside the tumer would be enough to move the needle and start getting lots of attention from different people/pharma. He stated that the "big guys" seem to be more interested in buying potential new technologies at a discount in the beginning stages of the research rather than develop it on their own. He said they are looking for as many shots on goal for as cheap as possible rather than trying to r&d it on their own. He was convinced based on what I showed him if we get through this first part and show some even a little anti tumor activity that we will start to see people making plays at thtx based on what he's seen in the last 10 years. Anyway thought I would share I thought it was interesting how these two top guys at Seattle children's knew very little about pdc tech. Which says to me that's where the muted response to some of our oncology stuff is coming from. Thtx has a real opportunity to be the first to make pdc treatment mainstream